NASH

New Research Study Will Evaluate the Investigational Drug Obeticholic Acid for Primary Biliary Cirrhosis

Leading medical centers around the world are beginning to enroll people with Primary Biliary Cirrhosis (PBC) in a Phase 3b clinical research study of an experimental drug, obeticholic acid (OCA). OCA is being developed for PBC patients who have an inadequate therapeutic response to, or who are unable to tolerate ursodiol, the only drug currently approved to treat the disease. The clinical study is currently recruiting adults aged 18 years and older with a definite or probably PBC diagnosis. 

For more information about the study or to find out if you are eligible to participate, you can speak with your doctor or visit www.PBC-Study.com, www.InterceptPharma.com or www.ClinicalTrials.gov.

  

IDN-6556-14


A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Emricasan, an Oral Caspase Inhibitor, in Subjects with Non-Alcoholic Steatohepatitis (NASH) Cirrhosis and Severe Portal Hypertension This is a phase 2 research study for patients with non-alcoholic steatohepatitis (NASH) cirrhosis and severe portal hypertension age 18 years and older. Participants will remain on the study and continue to receive the study investigational medication OR placebo until the study is completed unless they are removed or voluntarily end participation. It is estimated that patients will participate for a minimum of 26 weeks. During this time, participants will be evaluated by the study team approximately every 4 weeks.

 

747-303

A phase 3, double-blind, placebo-controlled multicenter study of the effectiveness and safety of an oral investigational study medication in patients with Nonalcoholic Steatohepatitis (NASH).

Enrollment Status: OPEN

This is a phase 3 research study for patients with NASH (Nonalcoholic Steatohepatitis) who have evidence of liver fibrosis. Participants will remain on the study and continue to receive the study investigational medication or placebo until the study is completed. It is estimated that patients will participate for a minimum of approximately 6 years. During this time, participants will be evaluated by the study team after the first month of treatment and then once every three months through Month 18. Following the Month 18 visit, participants will be evaluated two times per year (every six-months) for each additional year in the study.

For more information, call 612-870-5599 or visit www.NASH-study.com.

For more information or eligibility criteria, call our Research Hotline number at 612-870-5599, OR input the following information and we will follow up with you to discuss your interest:

ATTENTION: This form is not meant for transmitting medical, prescription or appointment information or to initiate direct communications with our health care providers. Calls of this nature will not be answered by email and should be directed to 612-871-1145. In the event of a medical emergency, dial 911. Emails are monitored Monday through Friday during regular business hours.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.